Krishna Institute of Medical Sciences Ltd (KIMS) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Krishna Institute of Medical Sciences Ltd (KIMS) reported gross revenue of INR 790 crores, a 29.7% YoY growth and 1% QoQ growth.
- EBITDA reached INR 205 crores, a 36.4% YoY increase but an 8.1% QoQ decline.
- EBITDA margin stands at 25.9% compared to 24.7% in Q3 FY24 and 28.5% in Q2 FY25.
- PAT is INR 93 crores, lower than Q2 FY25's INR 121 crores but higher than Q3 FY24's INR 77 crores.
- Consolidated EPS for 9 months is INR 7.1 (face value INR 2), a 15.6% YoY growth adjusted for share split.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.